Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
about
Use of fibrates in the metabolic syndrome: A reviewMetabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcomeLow incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.Iatrogenic severe depression of high-density lipoprotein cholesterol.Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.Treatment of metabolic syndrome with ankaflavin, a secondary metabolite isolated from the edible fungus Monascus spp.Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARγ) agonist with potent glucose-lowering properties.
P2860
Q26765234-24E9CAD5-A643-4CEB-A6DA-63E78A610332Q26799612-9404ED99-A14C-4354-95A6-DDFC97C4BBD5Q35650429-AF97C54F-BF91-4339-83D1-E03C266850BEQ36745091-A15F9DFB-13BC-41AA-9074-6E3B6C873705Q37464513-244523CC-91AC-4422-8EB7-05EA4DE0AAF7Q37597024-FF1011EB-33EA-4ECB-AF46-679C6AD16908Q38204282-5DC83771-1FE2-4DC5-9D59-32817E520CB0Q42803504-A695EEC0-5F6B-4B8D-ABDE-F2D921178B20Q50988033-DF591168-9658-4042-B1B0-EA6D8590D038
P2860
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
@en
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
@nl
type
label
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
@en
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
@nl
prefLabel
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
@en
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
@nl
P2093
P2860
P1433
P1476
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
@en
P2093
Balasubramani M
Ramachandran S
P2860
P356
10.1111/J.1464-5491.2007.02029.X
P577
2007-01-01T00:00:00Z